Cargando…

The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update

BACKGROUND: The 2017 Alzheimer’s disease (AD) Strategic Biomarker Roadmap (SBR) structured the validation of AD diagnostic biomarkers into 5 phases, systematically assessing analytical validity (Phases 1–2), clinical validity (Phases 3–4), and clinical utility (Phase 5) through primary and secondary...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boccardi, Marina, Dodich, Alessandra, Albanese, Emiliano, Gayet-Ageron, Angèle, Festari, Cristina, Ashton, Nicholas J., Bischof, Gérard N., Chiotis, Konstantinos, Leuzy, Antoine, Wolters, Emma E., Walter, Martin A., Rabinovici, Gil D., Carrillo, Maria, Drzezga, Alexander, Hansson, Oskar, Nordberg, Agneta, Ossenkoppele, Rik, Villemagne, Victor L., Winblad, Bengt, Frisoni, Giovanni B., Garibotto, Valentina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175304/ https://www.ncbi.nlm.nih.gov/pubmed/33688996 http://dx.doi.org/10.1007/s00259-020-05120-2

Ejemplares similares

Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Chiotis, Konstantinos, et al.
Publicado: (2021)

Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Bischof, Gérard N, et al.
Publicado: (2021)

The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
por: Ashton, N. J., et al.
Publicado: (2021)

Clinical validity of increased cortical uptake of [(18)F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework
por: Wolters, E. E., et al.
Publicado: (2021)

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Leuzy, A., et al.
Publicado: (2021)

Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding
por: Lemoine, Laetitia, et al.
Publicado: (2018)

Spatial Normalization of (18)F-Flutemetamol PET Images Using an Adaptive Principal-Component Template
por: Lilja, Johan, et al.
Publicado: (2019)

Tau PET imaging: present and future directions
por: Saint-Aubert, Laure, et al.
Publicado: (2017)

Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic
por: Bucci, Marco, et al.
Publicado: (2023)

Optimal timing of tau pathology imaging and automatic extraction of a reference region using dynamic [(18)F]THK5317 PET
por: Jonasson, My, et al.
Publicado: (2019)

Clinical impact of [(18)F]flutemetamol PET among memory clinic patients with an unclear diagnosis
por: Leuzy, Antoine, et al.
Publicado: (2019)

Tau PET imaging in neurodegenerative tauopathies—still a challenge
por: Leuzy, Antoine, et al.
Publicado: (2019)

Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia
por: Walker, Zuzana, et al.
Publicado: (2018)

Regional Disconnection in Alzheimer Dementia and Amyloid-Positive Mild Cognitive Impairment: Association Between EEG Functional Connectivity and Brain Glucose Metabolism
por: Smailovic, Una, et al.
Publicado: (2020)

Comparison of the contributions of female and male authors to medical research in 2000 and 2015: a cross-sectional study
por: Gayet-Ageron, Angele, et al.
Publicado: (2019)

Study design factors influencing patients’ willingness to participate in clinical research: a randomised vignette-based study
por: Gayet-Ageron, Angèle, et al.
Publicado: (2020)

In health research publications, the number of authors is strongly associated with collective self-citations but less so with citations by others
por: Jaksic, Cyril, et al.
Publicado: (2023)

Correction: In health research publications, the number of authors is strongly associated with collective self-citations but less so with citations by others
por: Jaksic, Cyril, et al.
Publicado: (2023)

Imaging biomarker roadmap for cancer studies
por: O’Connor, James P. B., et al.
Publicado: (2016)

Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline
por: Bucci, Marco, et al.
Publicado: (2021)

Prognostic model for traumatic death due to bleeding: cross-sectional international study
por: Ageron, Francois-Xavier, et al.
Publicado: (2019)

Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease
por: Leuzy, Antoine, et al.
Publicado: (2019)

Effects of Beta-Blockers on Melanoma Microenvironment and Disease Survival in Human
por: Wrobel, Ludovic Jean, et al.
Publicado: (2020)

Access to unauthorized hepatitis C generics: Perception and knowledge of physicians, pharmacists, patients and non-healthcare professionals
por: Garcia, Amandine, et al.
Publicado: (2019)

Female authorship of covid-19 research in manuscripts submitted to 11 biomedical journals: cross sectional study
por: Gayet-Ageron, Angèle, et al.
Publicado: (2021)

Analysis of peer reviewers’ response to invitations by gender and geographical region: cohort study of manuscripts reviewed at 21 biomedical journals before and during covid-19 pandemic
por: Ben Messaoud, Khaoula, et al.
Publicado: (2023)

Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients
por: Gayet-Ageron, Angèle, et al.
Publicado: (2018)

A new roadmap to improve translation of imaging biomarkers
por: Skwarski, Michael, et al.
Publicado: (2016)

Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison
por: Altomare, Daniele, et al.
Publicado: (2021)

Effect of tranexamic acid by baseline risk of death in acute bleeding patients: a meta-analysis of individual patient-level data from 28 333 patients
por: Ageron, Francois-Xavier, et al.
Publicado: (2020)

Alternative graphical displays for the monitoring of epidemic outbreaks, with application to COVID-19 mortality
por: Perneger, Thomas, et al.
Publicado: (2020)

Correction to: Alternative graphical displays for the monitoring of epidemic outbreaks, with application to COVID-19 mortality
por: Perneger, Thomas, et al.
Publicado: (2020)

Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development
por: Nordberg, Agneta
Publicado: (2011)

Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
por: Chiotis, Konstantinos, et al.
Publicado: (2023)

Biomarkers to Evaluate Androgen Deprivation Therapy for Prostate Cancer and Risk of Alzheimer’s Disease and Neurodegeneration: Old Drugs, New Concerns
por: Achard, Vérane, et al.
Publicado: (2021)

Barriers to Participation in a Patient Satisfaction Survey: Who Are We Missing?
por: Gayet-Ageron, Angèle, et al.
Publicado: (2011)

Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer’s disease
por: Carter, Stephen F., et al.
Publicado: (2018)

Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
por: Leuzy, Antoine, et al.
Publicado: (2021)

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
por: Ossenkoppele, Rik, et al.
Publicado: (2021)

A cross-sectional study on pelvic floor symptoms in women living with Female Genital Mutilation/Cutting
por: Binkova, Alzbeta, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j05m3j45gbvsj3ne5190hj6k0s